- Cellceutix Corporation (CTIX.OB) says it will "immediately advance" Brilacidin — the defensin-mimetic antibiotic acquired in the recent deal for PolyMedix — to a Phase 2b clinical trial for acute bacterial skin and skin structure infections.
- The company also says the compound may be effective for oral mucositis and as such, CTIX plans to finalize an IND and pursue an orphan designation for the treatment.
- Ultimately, the company sees quite a few exciting opportunities for the assets acquired from PolyMedix: "We believe we hit a home run with the PolyMedix acquisition, especially as it pertains to Brilacidin. The reality of owning these assets is now beginning to set in." (PR)
- More on Brilacidin here